Graph Therapeutics Raises $5M for Immune Drug Discovery

Vienna-based Graph Therapeutics has successfully closed a $5 million funding round, propelling its mission to develop novel therapeutics for inflammatory and immune-mediated conditions. The investment, spearheaded by Paris-based venture capital firm Daphni, significantly bolsters the company's financial runway, bringing its total capital raised to over $10 million, inclusive of non-dilutive funding.

This latest infusion of capital marks a strategic pivot for Graph Therapeutics, signaling a decisive shift from a primary focus on its proprietary technology platform to the tangible advancement of its internal drug discovery pipeline. The company intends to leverage these funds to accelerate the preclinical development of promising therapeutic candidates, while simultaneously expanding its platform's capabilities to foster strategic collaborations and out-licensing opportunities within the burgeoning biopharmaceutical sector.

The core of Graph Therapeutics' innovation lies in its sophisticated 'lab-in-the-loop' methodology. This unique approach synergistically combines advanced machine learning algorithms with live patient cell models to dissect intricate immune system functions. By meticulously analyzing multi-omics data derived from primary patient cells, the company aims to pinpoint critical disease mechanisms, identify novel drug targets, and discover predictive biomarkers, a crucial step in the precision medicine era.

The investor syndicate supporting this ambitious venture includes prominent venture capital firms SquareOne Venture Capital, Merantix Capital, and NAVEC Investment Management, all of whom participated in this round, underscoring their continued confidence in Graph Therapeutics' scientific vision. Furthermore, the company has benefited from substantial non-dilutive grants awarded by the Austrian Research Promotion Agency (FFG) and the Austria Wirtschaftsservice (aws), highlighting the critical role of public funding in nurturing deep-tech innovation within Austria's life sciences ecosystem.

The strategic involvement of public funding bodies like the FFG and aws, through programs such as "Austrian Life Sciences" and aws "Deep Tech Life Sciences Seed Financing," is instrumental in de-risking early-stage scientific research. These grants provide essential supplementary capital that allows companies like Graph Therapeutics to pursue groundbreaking scientific approaches, complementing private investment and paving the way for future clinical translation. The company's founding team brings a wealth of experience in AI-driven precision oncology, including prior work at Allcyte, which was notably acquired by Exscientia.

This funding round arrives at a time when the biotechnology sector is witnessing increased investor appetite for companies leveraging AI and advanced computational methods to accelerate drug discovery. The global AI in drug discovery market is projected to experience significant growth, driven by the need for more efficient and cost-effective R&D processes. Graph Therapeutics' focus on immunology and inflammation addresses a critical unmet medical need, with conditions like autoimmune diseases and chronic inflammatory disorders affecting millions worldwide and representing a multi-billion dollar therapeutic market.